Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
10
06
2020
accepted:
26
09
2020
revised:
18
09
2020
pubmed:
16
10
2020
medline:
24
6
2021
entrez:
15
10
2020
Statut:
ppublish
Résumé
Growing interest has been seen in using lysergic acid diethylamide (LSD) in psychiatric research and therapy. However, no modern studies have evaluated subjective and autonomic effects of different and pharmaceutically well-defined doses of LSD. We used a double-blind, randomized, placebo-controlled, crossover design in 16 healthy subjects (eight women, eight men) who underwent six 25 h sessions and received placebo, LSD (25, 50, 100, and 200 µg), and 200 µg LSD 1 h after administration of the serotonin 5-hydroxytryptamine-2A (5-HT
Identifiants
pubmed: 33059356
doi: 10.1038/s41386-020-00883-6
pii: 10.1038/s41386-020-00883-6
pmc: PMC8027607
doi:
Substances chimiques
Hallucinogens
0
Lysergic Acid Diethylamide
8NA5SWF92O
Ketanserin
97F9DE4CT4
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
537-544Références
Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008;14:295–314.
pubmed: 19040555
pmcid: 6494066
Nichols DE. Dark classics in chemical neuroscience: lysergic acid diethylamide (LSD). ACS Chem Neurosci. 2018;9:2331–43.
pubmed: 29461039
Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stampfli P, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT
pubmed: 30355445
pmcid: 6202055
Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 2017;27:451–7.
pubmed: 28132813
Kraehenmann R, Pokorny D, Vollenweider L, Preller KH, Pokorny T, Seifritz E, et al. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology. 2017;234:2031–46.
pubmed: 28386699
Liechti ME. Modern clinical research on LSD. Neuropsychopharmacology. 2017;42:2114–27.
pubmed: 28447622
pmcid: 5603820
Nichols DE, Johnson MW, Nichols CD. Psychedelics as medicines: an emerging new paradigm. Clin Pharmacol Ther. 2017;101:209–19.
pubmed: 28019026
Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology. 2017;42:2105–13.
pubmed: 28443617
pmcid: 5603818
Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry. 2019;86:792–800.
pubmed: 31331617
pmcid: 6814527
Carhart-Harris RL, Kaelen M, Bolstridge M, Williams TM, Williams LT, Underwood R, et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016;46:1379–90.
pubmed: 26847689
Dolder PC, Schmid Y, Mueller F, Borgwardt S, Liechti ME. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology. 2016;41:2638–46.
pubmed: 27249781
pmcid: 5026740
Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78:544–53.
pubmed: 25575620
Holze F, Vizeli P, Muller F, Ley L, Duerig R, Varghese N, et al. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology. 2020;45:462–71.
pubmed: 31733631
Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170–82.
pubmed: 29898390
pmcid: 6082376
Haile CN, Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Foulkes A, et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17:331–6.
pubmed: 24103211
Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2017;8:974.
pubmed: 29387009
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165–80.
pubmed: 27909164
pmcid: 5367551
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181–97.
pubmed: 27909165
pmcid: 5367557
Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2015;7:157–64.
pmcid: 4342293
Holze F, Duthaler U, Vizeli P, Muller F, Borgwardt S, Liechti ME. Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. Br J Clin Pharmacol. 2019;85:1474–83.
pubmed: 30883864
pmcid: 6595343
Yanakieva S, Polychroni N, Family N, Williams LTJ, Luke DP, Terhune DB. The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial. Psychopharmacology. 2019;236:1159–70.
pubmed: 30478716
Janke W, Debus G. Die Eigenschaftswörterliste. Göttingen: Hogrefe; 1978.
Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998;31:80–4.
pubmed: 9754838
Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE. 2010;5:e12412.
pubmed: 20824211
pmcid: 2930851
Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187:268–83. discussion 84-92
pubmed: 16826400
Liechti ME, Dolder PC, Schmid Y. Alterations in conciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology. 2017;234:1499–510.
pubmed: 27714429
Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol. 2015;29:1182–90.
pubmed: 26442957
pmcid: 5203697
Hysek CM, Vollenweider FX, Liechti ME. Effects of a β-blocker on the cardiovascular response to MDMA (ecstasy). Emerg Med J. 2010;27:586–9.
pubmed: 20378736
Zerssen DV. Die Beschwerden-Liste. Münchener informationssystem. München: Psychis; 1976.
Akimoto H, Oshima S, Sugiyama T, Negishi A, Nemoto T, Kobayashi D. Changes in brain metabolites related to stress resilience: Metabolomic analysis of the hippocampus in a rat model of depression. Behav Brain Res. 2019;359:342–52.
pubmed: 30447240
Dolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, et al. Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clin Pharmacokinet. 2017;56:1219–30.
pubmed: 28197931
pmcid: 5591798
Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME. Pharmacokinetics and concentration-effect relationship of oral LSD in humans. Int J Neuropsychopharmacol. 2015;19:pyv072.
pubmed: 26108222
pmcid: 4772267
Studerus E, Gamma A, Kometer M, Vollenweider FX. Prediction of psilocybin response in healthy volunteers. PLoS ONE. 2012;7:e30800.
pubmed: 22363492
pmcid: 3281871
Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202:513–20.
pubmed: 24594678
pmcid: 4086777
Vizeli P, Liechti ME. Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol. 2017;31:576–88.
pubmed: 28443695
Barrett FS, Preller KH, Herdener M, Janata P, Vollenweider FX. Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music. Cereb Cortex. 2018;28:3939–50.
pubmed: 29028939
Persson B, Heykants J, Hedner T. Clinical pharmacokinetics of ketanserin. Clin Pharmacokinet. 1991;20:263–79.
pubmed: 2036747
Reimann IW, Okonkwo PO, Klotz U. Pharmacokinetics of ketanserin in man. Eur J Clin Pharmacol. 1983;25:73–6.
pubmed: 6617728
de Almeida RN, Galvao ACM, da Silva FS, Silva E, Palhano-Fontes F, Maia-de-Oliveira JP, et al. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial. Front Psychol. 2019;10:1234.
pubmed: 31231276
pmcid: 6558429
Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, et al. Microdosing psychedelics: more questions than answers? An overview and suggestions for future research. J Psychopharmacol. 2019;33:1039–57.
pubmed: 31303095
pmcid: 6732823
Fadiman J, Korb S. Might microdosing psychedelics be safe and beneficial? an initial exploration. J Psychoact Drugs. 2019;51:118–22.
Passie T. The science of microdosing psychedelics. London: Psychedelic Press; 2019.
Hutten N, Mason NL, Dolder PC, Kuypers KPC. Motives and side-effects of microdosing with psychedelics among users. Int J Neuropsychopharmacol. 2019;22:426–34.
pubmed: 31152167
pmcid: 6600464
Bershad AK, Preller KH, Lee R, Keedy S, Wren-Jarvis J, Bremmer MP, et al. Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5:461–7.
pubmed: 32033922
Family N, Maillet EL, Williams LTJ, Krediet E, Carhart-Harris RL, Williams TM, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology. 2020;237:841–53.
pubmed: 31853557